Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras

Lung cancer is the most malignant tumor in the worldwide. About 3%‐5% non‐small cell lung cancer (NSCLC) patients carry anaplastic lymphoma kinase (ALK) gene fusions and receive great benefits from ALK‐targeted therapy. However, drug resistance inevitably occurs even with the most potent inhibitor d...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xiaoling, Zhong, Hui, Qu, Xiaojuan, Yang, Linsong, Jiang, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554663/
https://www.ncbi.nlm.nih.gov/pubmed/34766150
http://dx.doi.org/10.1002/mco2.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554663/
https://www.ncbi.nlm.nih.gov/pubmed/34766150
http://dx.doi.org/10.1002/mco2.42

Ejemplares similares